Q4 2024 Zevra Therapeutics Inc Earnings Call Transcript

Mar 11, 2025 / 08:30 PM GMT

Release Date Price: $8.07 (+0.88%)

Transcript 10-K8-K

Key Points

Positve

Zevra Therapeutics Inc (ZVRA) successfully transitioned to a commercial stage company with the launch of MyPIFA for Niemann-Pick disease Type C (NPC), marking a significant milestone.
The early launch of MyPIFA exceeded expectations with 109 patient enrollment forms received in Q4, indicating strong demand and unmet needs in the NPC community.
Zevra Therapeutics Inc (ZVRA) plans to expand MyPIFA's availability outside the US, with a focus on submitting a marketing authorization application in Europe in the second half of 2025.
The company entered into an agreement to monetize its priority review voucher for $150 million, providing non-dilutive capital to support future growth.
Zevra Therapeutics Inc (ZVRA) reported a record level of quarterly product revenue in Q4 2024, driven by MyPIFA's launch and other commercial activities.

Negative

Operating expenses for Q4 2024 were $24.5 million, contributing to a net loss of $35.7 million for the quarter.
The launch of Alprova for urea cycle disorders (UCDs) has progressed slower than expected, with limited patient pull-through and reimbursement support.
Zevra Therapeutics Inc (ZVRA) faces challenges in accelerating patient enrollment for its phase 3 Discover trial for vascular Ehlers-Danlos syndrome (vEDS).
Many commercial plans have not yet formalized reimbursement coverage for MyPIFA, posing potential hurdles for market access.
The company experienced a decrease in cash equivalents and investments by $20 million compared to the end of Q3 2024, highlighting financial pressures.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ZVRA.OQ - Zevra Therapeutics Inc
Q4 2024 Zevra Therapeutics Inc Earnings Call
Mar 11, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Please stand by. Your program is about to begin. If you need audio assistance during today's program, please press 0.

Good afternoon and thank you for joining Zevvro's Therapeutics 4th quarter and full year 2024 Financial Results and corporate Update conference call. Today's call is being recorded and will be available via the investor relations section of the company's website later today. The host for today's call is Nicole Ochner. Zev's Vice President of Investor relations and corporate communications.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.